MSD Animal Health – known as Merck Animal Health within the United States and Canada – has launched the first live vaccine with made with biotechnology that protects against three highly infectious diseases in poultry: Newcastle disease (ND), infectious bursal disease (IBD) and Marek’s disease (MD).
The company announced the launch of the vaccine, INNOVAX-ND-IBD -- on September 3 at the World Veterinary Poultry Association (WVPA) Congress.
The company announced that when given to chickens either in ovo or subcutaneously in the hatchery, it provides life-long protection for ND, IBD and MD simultaneously.
There are currently no treatment options available in Europe to combat these highly contagious infections which affect a range of systems, including the nervous, respiratory, immune and reproductive systems of many species of domestic and wild birds. If an outbreak hits a flock, the impact on the birds’ welfare and productivity is significant.
If left uncontrolled, these diseases not only affect the health of the birds but can also wipe out entire flocks, resulting in a huge economic loss for poultry producers,” said Dr. Taylor Barbosa, DVM, PhD, ACPV, head of Poultry, MSD Animal Health. “Prevention is the best method of protecting poultry from these devastating diseases. INNOVAX-ND-IBD makes it easier for producers to protect their flocks with a single vaccine, which does not interfere with other live respiratory vaccines, giving vaccinated chickens a full range of protection and producers more flexibility when designing the vaccination program.”
By protecting against multiple diseases with a single injection, INNOVAX-ND-IBD also improves poultry welfare by reducing the stress associated with multiple needle sticks and speeds the vaccination process for the producer, the company stated.
INNOVAX-ND-IBD is a multivalent live vaccine that uses the “dual-construct technology” in a live herpes virus of turkey (HVT), a persistent virus containing one ND gene and one IBD gene inserted into the genome, to provide life-long immunity. INNOVAX-ND-IBD does not contain live ND or IBD viruses and cannot induce virus spread, revert to virulence or interfere with other live respiratory vaccines. In addition, there are no post-vaccinal reactions because HVT is safe and nonpathogenic to chickens. Importantly, maternal antibodies do not interfere with INNOVAX-ND-IBD. It was introduced in Peru in June of this year.
Together with the Protectotype (Nobilis Ma5 and Nobilis 4/91) and the live ND products (Clone 30 and ND C2), the INNOVAX family provides the most complete selection of vaccines to be applied in the hatchery.